Immunoassay for Capsular Antigen of Bacillus anthracis Enables Rapid Diagnosis in a Rabbit Model of Inhalational Anthrax.
Inhalational anthrax is a serious biothreat. Effective antibiotic treatment of inhalational anthrax requires early diagnosis; the further the disease has progressed, the less the likelihood for cure. Current means for diagnosis such as blood culture require several days to a result and require advanced laboratory infrastructure. An alternative approach to diagnosis is detection of a Bacillus anthracis antigen that is shed into blood and can be detected by rapid immunoassay. The goal of the study was to evaluate detection of poly-γ-D-glutamic acid (PGA), the capsular antigen of B. anthracis, as a biomarker surrogate for blood culture in a rabbit model of inhalational anthrax. The mean time to a positive blood culture was 26 ± 5.7 h (mean ± standard deviation), whereas the mean time to a positive ELISA was 22 ± 4.2 h; P = 0.005 in comparison with blood culture. A lateral flow immunoassay was constructed for detection of PGA in plasma at concentrations of less than 1 ng PGA/ml. Use of the lateral flow immunoassay for detection of PGA in the rabbit model found that antigen was detected somewhat earlier than the earliest time point at which the blood culture became positive. The low cost, ease of use, and rapid time to result of the lateral flow immunoassay format make an immunoassay for PGA a viable surrogate for blood culture for detection of infection in individuals who have a likelihood of exposure to B. anthracis.
University of Nevada School of Medicine, Reno, Nevada, United States of America.
Marcellene A
MA
Gates-Hollingsworth
Battelle Biomedical Research Center, Columbus, Ohio, United States of America.
Mark R
MR
Perry
InBios International, Inc., Seattle, Washington, United States of America.
Hongjing
H
Chen
InBios International, Inc., Seattle, Washington, United States of America.
James
J
Needham
InBios International, Inc., Seattle, Washington, United States of America.
Raymond L
RL
Houghton
InBios International, Inc., Seattle, Washington, United States of America.
Syamal
S
Raychaudhuri
University of Nevada School of Medicine, Reno, Nevada, United States of America.
Mark A
MA
Hubbard
University of Nevada School of Medicine, Reno, Nevada, United States of America.
Thomas R
TR
Kozel
D000818:Animals; D000881:Anthrax / Q000175:diagnosis* / Q000382:microbiology; D000907:Antibodies, Bacterial / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000915:Antibody Affinity / Q000276:immunology; D000942:Antigens, Bacterial / Q000276:immunology*; D001408:Bacillus anthracis / Q000276:immunology; D016667:Bacterial Capsules / Q000276:immunology*; D015415:Biomarkers; D042241:Early Diagnosis; D007118:Immunoassay / Q000379:methods; D007074:Immunoglobulin G / Q000276:immunology; D007159:Immunologic Tests / Q000379:methods; D011099:Polyglutamic Acid / Q000031:analogs & derivatives* / Q000097:blood / Q000276:immunology; D011817:Rabbits; D012141:Respiratory Tract Infections / Q000175:diagnosis* / Q000382:microbiology
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D015415:Biomarkers; D007074:Immunoglobulin G; D011099:Polyglutamic Acid